NASDAQ · FBIOP

Fortress Biotech, Inc.. 9. 375% Cumulative Redeemable Perpetual

$18.73 -$0.16 (-0.85%) 1D Market open

Key Metrics

$497.26M
Market cap
3.89×
P/E · TTM
$79.30M
Revenue · TTM
$127.77M
Net income
EPS · TTM $4.83
Dividend yield 0.1%
Free cash flow
Beta · 1Y 0.32
EBITDA · TTM −$55.27M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 26
    The stock moved +9.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 26
  • Feb 23
    The stock moved +23.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 23

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap
Enterprise value$278.92M
Shares outstanding
52-wk range$6.27 – $21.43
Avg volume · 20D15.4K
Net cash $218.34M
Book value / share$6.13
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Fortress Biotech, Inc.. 9. 375% Cumulative Redeemable Perpetual
IPO dateNov 14, 2017
Employees78

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E3.89
P/S6.27
P/FCF
EV/EBITDA
EV/Sales3.52
Graham №$25.82

Profitability

Gross
Operating -70.2%
Net 161.1%
FCF
ROE / ROIC 138.2% · —

Financial Health

Current ratio2.86
Quick ratio2.77
Debt / equity0.23
Debt / EBITDA -0.68
Net cash $218.34M
Working capital$192.09M

Cash Flow · TTM

Operating CF $157.64M
Capex
Free cash flow
Buybacks
Dividends paid $498.00K
Shareholder yield 0.1%

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

-0.2
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

$25.82 vs $18.80
Trades below classic defensive value — Graham-cheap
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings